Cause of blood clots after AstraZeneca probably found

Scientists believe they have found the cause of the very rare side effect of the AstraZeneca vaccine in which blood clots (thrombosis) are formed.

Researchers in Wales and the United States, according to the BBC found that a protein in the blood is attracted to an important part of the vaccine.

AstraZeneca’s vaccine is estimated to have saved a million lives worldwide by providing protection against the coronavirus. Earlier this year, however, the jab was discredited because there was a possible link between the vaccine and serious blood abnormalities, so that it was decided in the Netherlands to no longer use the vaccine.

More likely after infection

Researchers from AstraZeneca joined the British and American scientists. A spokesperson for the pharmaceutical company explains to the BBC found that the risk of blood clots is greater after infection with the corona virus than after a vaccination. However, it is still not entirely clear why the side effect occurs in some cases.

The AstraZeneca vaccine, which consists of genetic material and a common cold virus, is normally injected into a muscle, but sometimes some of the drug gets into the bloodstream. Then there is a chance that it will attract a certain protein in the blood, which in rare cases causes an immune system reaction. That response causes antibodies to attack the injected cold virus, which can lead to the blood clots.

Also read: Vaccination rate in Limburg increases by 2 to 3 percent: that’s how it is in your municipality

While this probably explains what is causing the blood clots, the researchers say “many steps still need to be taken.” For example, it is not yet clear why some people are more susceptible to the side effect than others.

read more  Osivax obtains 10 million euros from Bpifrance for its universal flu vaccine

.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Never miss any important news. Subscribe to our newsletter.